Senior Leadership Team

Mr. Grossman has been the driving force behind ADMA Biologics’ mission to develop and bring to market novel plasma-derived products to address certain unmet medical needs for immune compromised patients.

He began his career as a hospital-based plasma products sales representative focusing on immune compromised patients. This opportunity provided him with a first-hand view of certain challenges patients faced while gaining an understanding of how some patients' medical needs are handled by treating clinicians. Mr. Grossman has over 25 years of experience in the blood and plasma products industry which includes experience in launching new products, building and managing national and international sales forces as well as managing and designing clinical trials. Additionally, he has negotiated and completed numerous business development transactions. Under his leadership, Mr. Grossman brought ADMA public in 2013 and has completed over $300M in capital markets financing and debt transactions throughout his career.

Mr. Grossman led the asset acquisition of the Biotest Therapy Business Unit in 2017, which transformed ADMA Biologics into one of a handful of vertically integrated plasma products manufacturing companies based in the US. Subsequent to the asset acquisition, he is credited with leading the successful integration of business operations, revamping and overhauling the site-wide quality and compliance functions, and leading the regulatory affairs strategy resulting in FDA approvals for BIVIGAM®’s Prior Approval Supplement (PAS) and ASCENIV™’s Biologics License Application (BLA), as well as the receipt of a new FDA license for the Boca Raton manufacturing plant.

Mr. Grossman has been a member of the ADMA Biologics Board of Directors since 2007, has served as its President and Chief Executive Officer since October 2011, and was the President and Chief Operating Officer between 2007 and October 2011. In 2016, he was issued several patents, which are the basis for the manufacturing methods and composition for ASCENIV™. Prior to founding ADMA, Mr. Grossman was the Executive Vice President of National Hospital Specialties and GenesisBPS, positions he held between 1994 and 2011. Previously, he worked at MedImmune, Inc. as part of the marketing team for respiratory syncytial virus and cytomegalovirus immunoglobulins and at the American Red Cross, where he participated in the launch of new products with the Biomedical Services division.

Mr. Grossman is a graduate of American University, receiving a BS in Business Administration, with a specialization in International Business and Marketing. Mr. Grossman is the son of Dr. Jerrold B. Grossman, ADMA's Vice-Chairman and co-founder. Mr. Grossman was chosen to serve on the Board because he has broad expertise in the plasma products industry, and as the Company's Chief Executive Officer, he is able to provide the Board with critical insight into the day-to-day operations of the Company.

Mr. Lenz joined ADMA as Vice President, Chief Financial Officer in May 2012 and was instrumental in preparing the Company to go public and begin trading on the NASDAQ in October 2013. In June 2018, Mr. Lenz was promoted to Executive Vice President and Chief Financial Officer.  Mr. Lenz co-led the Biotest Therapy Business Unit (“BTBU”) acquisition team.  In this role, Mr. Lenz was responsible for integrating all financial reporting and financial operations, as well as ensuring the seamless integration of all human resources activities and information technology systems during and after the transaction.

Mr. Lenz’s financial and operational leadership experience includes completing numerous capital markets equity financings, negotiating multiple significant credit facilities, leading strategic transactions, licensing and collaboration arrangements throughout his 25-year career, serving both public and private companies in the life sciences and medical device sectors. He leads ADMA’s investor relations efforts and continues to oversee the Company’s financial reporting and SOX compliance activities amongst other operational duties.

Prior to joining ADMA, Mr. Lenz was at CorMedix Inc., a developmental-stage pharmaceutical and medical device company, where he held the position of Chief Financial Officer from February 2010 to May 2012 and Chief Operating Officer and Chief Financial Officer from January 2012 to May 2012. Prior to joining CorMedix, Mr. Lenz served as Chief Financial Officer of Arno Therapeutics, Inc. from July 2008 to February 2010, Chief Financial Officer of VioQuest Pharmaceuticals, Inc. from April 2004 to June 2008, Controller of Chiral Quest, Inc., a subsidiary of VioQuest Pharmaceuticals, from October 2003 to March 2004, Controller of Smiths Detection from July 2000 to October 2003, and senior auditor at KPMG LLP from October 1998 to July 2000.

Mr. Lenz received a BS from Rider University, an MBA from Saint Joseph’s University and is a licensed Certified Public Accountant in New Jersey.

Mr. Lenz is the finance committee co-chairperson for BioNJ.  He has actively been involved in advising biotechs, pharmaceutical companies, venture capitalists, debt lenders and hedge funds.

Mr. Lenz has received multiple awards for his various accomplishments as CFO, which include:  Best Growth Manager, Financier of the Year, Public Company and Capital Success.

As Senior Vice President of Compliance and Project Operations for ADMA Biologics, Ms. Kestenberg is responsible for ensuring Company activities comply with regulations and the expectations of governing bodies as well as oversees company-wide project planning, project management, and oversight for clinical programs and operations.

Along with the executive team, Kaitlin was instrumental in conducting due diligence on the Biotest Therapy Business Unit acquisition as well as playing an integral role in integration of corporate operations, compliance and FDA-regulated functions. She led significant portions of ADMA’s compliance and quality assurance overhaul, worked on teams developing novel regulatory affairs strategies, led the team responsible for drafting the ASCENIV™ BLA and other significant regulatory submissions and is credited with preparing the company for a successful FDA inspection post acquisition. Ms. Kestenberg has participated in and led numerous FDA interactions for ADMA and has attended multiple face-to-face FDA meetings during her tenure.

Ms. Kestenberg joined ADMA Biologics as Clinical Research Manager in 2011 and has received multiple promotions and positions of increasing responsibility. Prior to joining ADMA, she held roles of increasing responsibility in clinical operations, quality operations and compliance at Acorda Therapeutics and Merck.

Ms. Kestenberg has over 12 years of project management and clinical operations experience including successful Phase 3 clinical trials and subsequent regulatory filings. She was responsible for all operational aspects and site management and oversite of ADMA’s Phase 3 clinical program used as the basis for ADMA’s drug approval for ASCENIV™. She has led cross-functional teams across numerous therapeutic areas including immunology, infectious diseases, multiple sclerosis, congestive heart failure, acute spinal cord injury, HIV, hepatitis Clostridioides difficile, and diabetes.

She holds a BA from the State University of New York at Albany and an MSJ from Seton Hall University.

Mr. Chambers joined ADMA Biologics in April 2023 as the Vice President, Quality. He is responsible for ensuring the continued high-performance of ADMA’s Quality Management System, while partnering closely with development, manufacturing, and commercial colleagues to drive a culture of quality excellence and compliance.

Prior to joining ADMA, Mr. Chambers was the Vice President of Global Quality at VBI Vaccines where he led the quality organization during the development and commercial launch of the company’s lead hepatitis B vaccine candidate. Mr. Chambers has more than 25 years of experience in the field of quality and has successfully led multiple regulatory inspections, both foreign and domestic. His broad background includes quality and operational leadership positions at Merck, Charles River Laboratories, BioReliance, and ElevateBio.

Mr. Chambers holds a BS in Biology from Western Carolina University.

Neal has a talent for building world-class sales teams and leading them to produce consistently stellar results.

In his prior role at Kedrion Biopharma, he held the position of Vice President, Commercial Head for more than 8 years; January 2012 to September 2020 – launching the commercial organization in the United States. He was responsible for hiring and developing the North American commercial organization. The company’s areas of expertise include immunology, neurology, critical care, women’s health, and bleeding disorders. Neal led the launch or re-launch of 6 biologic products within those specialties. Neal’s success is centered on building a culture based on strong social responsibility. He models his teams around the obligation to the patients they serve, the colleagues they partner with, and the communities in which they live.

Neal has spent more than 30 years successfully leading departments and organizations; honing his leadership skills at companies such as United Therapeutics, Novo Nordisk, Wyeth, Genetics Institute and Bristol-Myers Squibb. He has previously served as the Chairman of the Plasma Protein Therapeutics Association (PPTA) North American Advisory Board.

Neal received his BS degree in Pharmacy from the University of Rhode Island and continued his training at Wharton College with courses on strategic leadership, financial business management, and team building.

Mr. Daniel Garcia is Vice President of IgG Product Management for ADMA Biologics and is responsible for management of IgG products, serving on strategic business and continuous improvement assignments.  

Mr. Garcia joined ADMA Biologics April of 2016 as the VP of Manufacturing and Technical Operations. Prior to joining ADMA he was Senior Production Manager at Baxter Healthcare, an integral team member developing a new IGIV product. As Senior Director of Operations and Technical Development at Emergent Biosolutions, Mr. Garcia was on the development team and later headed the manufacturing and process development functions in the production of anthrax vaccine (Biothrax), a commercial vaccine for the DOD in support of US Military personnel. At Shanghai RAAS Blood Products, Mr. Garcia led a project as VP of Operations, constructing a 3 million liter automated blood fractionation plant in compliance with US FDA, EMEA and ISO-9001 accreditation standards. Mr. Garcia served as COO at Biocell Laboratories where he was responsible for developing and commercializing numerous FDA-approved clinical controls, calibrators and medical devices.  At Molecular GPS, as VP of Manufacturing, Mr. Garcia designed and constructed a cGMP modular cleanroom production facility to manufacture targeted small molecule anti-cancer therapeutics and vaccines.

With over 30 years of Pharmaceutical, Manufacturing, and Operations experience in production of FDA-licensed small volume parenteral therapeutics, vaccines and medical devices, Mr. Garcia led development, manufacturing and engineering teams across numerous therapeutic areas. He holds a BA from California State University Los Angeles and an MS from California State University Northridge.

Mr. Janek joined ADMA Biologics in May of 2021. Prior to joining ADMA, Mr. Janek was a Site Head and integral team member of the Plasma Leadership Team with Takeda. Mr. Janek started his career in 1994 with Alcon Laboratories, an ophthalmic pharmaceutical company in Fort Worth, Texas, and he went on to serve Alcon for 20 years in roles of increasing management responsibility, including the last 6 years with Alcon as a Site Head in Sao Paulo, Brazil.  Mr. Janek returned to North America in 2014 and held positions of increasing responsibility from Associate Director with Gilead to Site Head with Takeda.

With over 25 years of operations management experience in aseptic formulation, aseptic filling and finishing, including more than 10 years in a Site Head capacity leading manufacturing of globally regulated and licensed pharmaceuticals, biologics (plasma), and medical devices, Mr. Janek has built a strong career in highly technical environments across multiple countries, companies and sites.

Mr. Janek has a proven track record in putting the patient first by improving manufacturing operations, driving regulatory compliance, improving safety, deploying Lean Six Sigma, assuring business continuity, leading turn-around, developing people and teams, and building and growing cost-competitive organizations.

Mr. Janek is an iTLS Certified Expert and Black Belt in Theory of Constraints, Lean Six Sigma. He holds a BA in Biology from Texas A&M University and an MA in Pharmaceutical Manufacturing from Stevens Institute of Technology.

As Vice President, Market Access and National Accounts for ADMA Biologics, Mr. Least brings experience of more than 30 years in the healthcare industry with a focus on specialty product manufacturing, sales, distribution, and commercial operations. Previously as Vice President of Sales for ASD Healthcare, he helped to grow specialty distribution from $9B to over $15B in annual sales. Mr. Least has held various roles and responsibilities including sales, sales leadership, marketing, medical affairs, training, account management, business development, and executive leadership. He has worked for large premier manufacturers and distributors (Searle, Pfizer, Eisai, Johnson & Johnson, AmerisourceBergen), as well as entrepreneurial biotech companies. His extensive knowledge and expertise has resulted in consistent success, with a unique perspective of the US specialty care market and the challenges facing manufacturers, distributors, healthcare providers, health systems, and academic medical centers of excellence.

Mr. Pantello is Vice President of Marketing and Corporate Development for ADMA Biologics. He is responsible for leading marketing and business development efforts across all the ADMA immunoglobulin brands.

Prior to joining ADMA Biologics in January of 2018, Mr. Pantello was the account management lead supporting ADMA’s launch preparation activities at H4B Chelsea and Havas Health. At H4B/Havas, he worked hand in hand with the executive team at ADMA Biologics for more than 4 years dissecting the layers of the plasma products market, leading all market research and focus group activities to gain insights and form the basis for the company’s marketing strategies. Drew brings to ADMA the experience of holding various roles of increasing responsibility and working on product launches across a wide range of therapeutic categories for more than 20 years in pharmaceutical market research, advertising, and marketing. He has held positions at LM&P, Euro RSCG Life, H4B Chelsea, and Havas Health across Account Management and Business Development functions. He was responsible for leading numerous major product launches for brands across immunology, HIV, infectious disease, diabetes, and neuroscience.

Mr. Pantello holds a BA in History from Ramapo College of New Jersey.

Mr. Space is the Vice President of Supply Chain and Facility Operations.

He joined ADMA Biologics in September 2018. Prior to this, he worked for Hoffman-La Roche, holding leadership positions in process development, engineering, production, supply chain, finance, IT, and site management. With Roche, he worked at several sites across the United States and internationally.

Mr. Space has more than 30 years of varied operational experience in the pharmaceutical industry. He led significant capital projects including the design and construction of a $50 million vitamin plant and a $350 million Greenfield active pharmaceutical ingredient facility. He led a supply chain expansion program for an antiviral targeted at the prevention and treatment of a threatened global influenza pandemic.

Mr. Space holds an MA in Business Administration from Rutgers University and a BA in Chemical Engineering from the University of Delaware.

As the Vice President, Operations for ADMA BioCenters, Mr. Stremming is responsible for overseeing all aspects of the Plasma Services organization, including driving plasma collections and revenue growth, quality control, and ensuring continued regulatory compliance across all ADMA BioCenters. Mr. Stremming works closely with cross-functional teams within both ADMA BioCenters and ADMA Biologics to identify opportunities for process optimization and cost reduction, while building and maintaining relationships with key industry partners and stakeholders.

Mr. Stremming joined ADMA BioCenters in April 2023. Prior to joining ADMA, Mr. Stremming was the President of Interstate Blood Bank, Inc., President of BPC, and Vice President of the Southeast Plasma Business Unit within the Grifols Organization. Mr. Stremming started his career as a Center Manager in 2000 with Alpha Therapeutic, a plasma company headquartered in Los Angeles, CA. Over the past 20 years, Mr. Stremming worked at Grifols with increasing responsibilities. His roles included Regional Operations Manager, Associate Director of Operations, Director of Program Management, Senior Director of Business Integration (M&A), and finally Vice President of Southeast Plasma Operations.

He holds a BA from Washburn University, as well certifications in Lean Six Sigma, Project Management, and Mergers & Acquisitions.

Mr. Tade joined ADMA Biologics in June of 2023 as the Vice President, Financial Operations. Prior to joining ADMA, Mr. Tade held the position of Vice President Finance, Commercial Packaging Technology and prior to that Vice President Finance, Development and Manufacturing for PCI Pharma Services. Prior to working for PCI Pharma Services Mr. Tade held the role of Vice President Finance, Operations & Quality for Baxter based in Illinois and prior to that Vice President, Operations Finance for Becton Dickinson based in Switzerland.

With over 20 years of experience in the Medical Device industry, leading global supply chain and manufacturing operations finance teams, Mr. Tade has built a strong career across multiple countries and multinational organizations.

Mr. Tade earned a Bachelor of Science degree in Finance from California State University Long Beach, and a Master of Arts degree in Organizational Leadership from Gonzaga University.

Dr. Wetzstein is the Vice President, Medical Affairs and Scientific Engagement for ADMA Biologics. In this role, he is responsible to ensure effective and collaborative medical relationships and scientific interchange with ADMA Biologics key medical healthcare partners.

Gene has a diverse and accomplished career spanning 20+ years in the academic and institutional practice setting. He earned his BS Pharmaceutical Sciences/Chemistry and Doctorate of Pharmacy from North Dakota State University. He then completed a Pharmacy Practice Residency at the University of Utah Hospitals and Clinics and an Oncology/Hematology/HSCT Specialty Residency at Moffitt Cancer Center & Research Institute. He has been Board Certified in Oncology Pharmacy (BCOP) since 2000 and a licensed consultant (FL) pharmacist since 2010.  

Following his specialty residency training, Gene accepted a clinical specialist role in Malignant Hematology/Infectious Disease at Moffitt Cancer Center. Over 18+ years, he held progressive leadership roles both within the clinical/research and administrative settings, heading up Clinical Services/Supportive Care Research and later Chief Pharmacy Officer overseeing the entire pharmacy enterprise. Gene has held multiple national leadership roles including Chair, Pharmacy Leadership Committee of the Alliance of Dedicated Cancers (ADCC). He has also served on the Board of Directors of the Florida Society of Clinical Oncology (FLASCO). Gene is recognized throughout the county as a true pharmacy thought leader and has been invited on multiple occasions to speak on oncology/hematology/supportive care related topics.  

Prior to joining ADMA Biologics, Gene was at TESARO/GSK for the last 3 years in customer facing medical roles. He worked closely with Institutional/Practice key decision makers in alleviating any potential obstacles or challenges that may arise with the integration of a new product into their Systems/Formularies. As Head, US Field Value, he worked closely with internal partners to develop/expand clinical data sets, refine, package, and deliver these critical product messages to key institutions/practices/centers of excellence.

Dr. Gruenglas is Executive Director, Government Affairs, Health Policy and Scientific Communications, at ADMA Biologics. In this capacity, he works with federal and state stakeholders to develop and advocate for policy that impacts the IVIG therapeutic area, plasma-derived therapies, and biopharmaceuticals. In this role he conducts research in policy, pharmacoeconomics, and ethics. Prior to this he was a Managing Partner and Executive Vice President for several life science consultancies, with a focus on oncology commercialization, health policy, and managed care. Dr. Gruenglas earned his doctorate in health sciences from Massachusetts College of Pharmacy and Health Sciences, where he was elected to Phi Kappa Phi and Alpha Eta honor societies. He holds MAs in bioethics from Harvard Medical School and English Literature from Brooklyn College-CUNY, and a Certificate in Legislative Studies from the Government Affairs Institute at Georgetown University. Dr. Gruenglas is faculty at the College of Arts & Sciences, Boston University, and serves as a volunteer firefighter/EMT in Massachusetts.

Ms. Klostermeyer is the Executive Director, Supply Chain for ADMA Biologics. She is responsible for logistics, inventory control, distribution of finished goods, and production scheduling. She develops strategic plans and processes to improve productivity, quality, and efficiency of operations.

Ms. Klostermeyer has over 20 years’ experience in the biologics industry. She has held management positions with increasing responsibility at the ADMA Biologics manufacturing site across Supply Chain, Accounting and Information Technology.

Ms. Klostermeyer holds a BA in operations management from Florida Atlantic University in Boca Raton, FL.

Ms. Petersen is the Executive Director of Human Resources for ADMA Biologics. She is responsible for leading the human resources department including talent acquisition, human resources operations, human resources compliance, employee relations as well as benefits and payroll administration.

Ms. Petersen joined ADMA Biologics in October 2022. Prior to joining ADMA, she worked for the last 11 years with Exelon, an energy company, where she held leadership roles in Human Resources with their nuclear generation division and later with distribution and transmission. She has over 25 years of experience with Fortune 100 companies in the field of human resources.

Ms. Petersen holds a BA in Social Science with a pre-law endorsement along with an MBA from Strayer University with a concentration in Human Resources. She has a certificate from the RBL Group in Strategic HR and an Organization Leadership certificate the Institute of Nuclear Power Operations (INPO). She is Six Sigma certified and applies the foundation of lean principles to all aspects of human resources. She has been an active member of the Society of Human Resource Management (SHRM) since 2008.